Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-08
A
Ahmad Mazin M. Safar
Role not yet determined Is this you? Add your title
Also affiliated: University of Arkansas Medical Center (2022–2024); Central Arkansas Veterans Healthcare System (2024)
1 h-index
8 pubs
5 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Ahmad Mazin M. Safar's research has focused on molecular mechanisms within cancer, particularly in non-small cell lung cancer and prostate cancer. His work includes investigating DNA methylation as a prognostic tool for non-small cell lung cancer, with publications detailing methylation profiling and promoter hypermethylation for molecular staging. Safar has also explored the potential of designer T cells for prostate cancer therapy. His research interests extend to the metabolic aspects of cancer, with studies on the anabolic potential of amino acid mixtures in advanced non-small cell lung cancer and the relationship between pre-diagnosis blood glucose and prognosis in women with breast cancer. Safar has also examined gene expression and DNA methylation in breast cancer. His recent work includes a case report on the emergence of chronic lymphocytic leukemia during COVID-19 admission. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Farah Mazahreh and Liyan Mazahreh, with whom he has shared multiple publications.
Metrics
- h-index: 1
- Publications: 8
- Citations: 5
Selected Publications
-
Abstract 3051: Enhancing matchmaking in targeted therapy (TT) for cancer (ca): Beyond the ‘arranged’ criteria (2026)
-
Abstract 6288: Rational pairing of tumors with off-patent targeted therapies (TT): Next3 generation sequencing with global applications for the unprivileged patients. (2026)
-
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)
-
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA) (2025)
-
Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better (2025)
-
Abstract 5582: Interrogating the K-ras/p53 transcriptional readout for synthetic lethality applications (2025)
-
A Case Report on Pulmonary Tumor Embolism in a Patient With a Metastatic Gastrointestinal Stromal Tumor Invading the Inferior Vena Cava: Tumor or Thrombus? (2025)
-
Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing (2025)
-
Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis (2025)
-
Case of Immune Checkpoint Inhibitor Induced Myasthenia Gravis (2024)
-
Abstract 3856: Nodal metastasis as an immune indicator in cancer (ca) therapy (2024)
-
Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications (2024)
-
Abstract 1567: Honing in on the metastasis machinery (2024)
-
Weight loss (WL) as a predictive factor for immune oncology (IO). (2023)
-
Validity of mutations as a cancer chronometer. (2022)
Collaboration Network
Top Collaborators
Farah Mazahreh
University of Arkansas for Medical Sciences
7 shared publications
In database
- Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis
- Weight loss (WL) as a predictive factor for immune oncology (IO).
- Abstract 1567: Honing in on the metastasis machinery
- Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications
- Abstract 3856: Nodal metastasis as an immune indicator in cancer (ca) therapy
Showing 5 of 7 shared publications
Laura F. Hutchins
University of Arkansas for Medical Sciences
6 shared publications
In database
- Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- Hydralazine-demethylating systemic therapy for breast cancer
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
- Editorial Clubs as a New Teaching Tool in Postgraduate Training
Showing 5 of 6 shared publications
Liyan Mazahreh
University of Arkansas for Medical Sciences
5 shared publications
In database
- Tumor Response to Immune-Oncology Therapy Despite High-Dose Steroid Intervention in a Patient With Papillary Renal Cell Carcinoma and Immune-Related Myasthenia Gravis
- Weight loss (WL) as a predictive factor for immune oncology (IO).
- Abstract 1177: The chronology of immune-related adverse events (irAEs)-mechanistic implications
- Ongoing Radiographic Response for Over 20 Months in Metastatic Cancer Without Continued Immune Checkpoint Inhibitor (ICI) Dosing
- Abstract 3214: The duration of immune checkpoint inhibitors (ICI) in oncology: Longer is not better
Paulette Mehta
Central Arkansas Veterans Healthcare System
4 shared publications
In database
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
- Editorial Clubs as a New Teaching Tool in Postgraduate Training
- Triaging Referrals as Part of Hematology/Oncology Fellowship Training
- Managing Erythropoietin Usage in a Large Veterans Healthcare System.
Issam Makhoul
University of Arkansas for Medical Sciences
4 shared publications
In database
- Hydralazine-demethylating systemic therapy for breast cancer
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
- Therapeutic Implications of Angiogenesis in Cancer
- Triaging Referrals as Part of Hematology/Oncology Fellowship Training
Craig A. Cooney
University of Arkansas for Medical Sciences (US)
3 shared publications
- Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System
- CHST11 gene expression and DNA methylation in breast cancer
- Promoter Hypermethylation for Molecular Nodal Staging in Non–Small Cell Lung Cancer
A. Shwaiki
University of Arkansas for Medical Sciences (US)
3 shared publications
- Promoter Hypermethylation for Molecular Nodal Staging in Non–Small Cell Lung Cancer
- The impact of platelet count (Plt#) on outcome in curable non-small cell lung cancer (NSCLC)
- The impact of platelet count (Plt#) on outcome in curable non-small cell lung cancer (NSCLC)
Chun‐Yang Fan
University of Arkansas for Medical Sciences (US)
3 shared publications
- Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System
- Promoter Hypermethylation for Molecular Nodal Staging in Non–Small Cell Lung Cancer
- Hydralazine-demethylating systemic therapy for breast cancer
Fariba Jousheghany
Winthrop Rockefeller Foundation
2 shared publications
In database
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- CHST11 gene expression and DNA methylation in breast cancer
Eric R. Siegel
Winthrop Rockefeller Foundation
2 shared publications
In database
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- CHST11 gene expression and DNA methylation in breast cancer
Thomas Kieber‐Emmons
Winthrop Rockefeller Foundation
2 shared publications
In database
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- CHST11 gene expression and DNA methylation in breast cancer
Behjatolah Monzavi‐Karbassi
Winthrop Rockefeller Foundation
2 shared publications
In database
- Pre-diagnosis blood glucose and prognosis in women with breast cancer
- CHST11 gene expression and DNA methylation in breast cancer
Horace J. Spencer
University of Arkansas for Medical Sciences
2 shared publications
In database
- Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System
- Promoter Hypermethylation for Molecular Nodal Staging in Non–Small Cell Lung Cancer
Xiaobo Su
Central Arkansas Veterans Healthcare System (US)
2 shared publications
- Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System
- Promoter Hypermethylation for Molecular Nodal Staging in Non–Small Cell Lung Cancer
M.P. Engelen
University of Arkansas for Medical Sciences (US)
2 shared publications
- High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer
- Reduced Plasma Short-Chain Fatty Acid (SCFA) Concentrations Are Not Associated With Markers of Muscle Health in Non-Small Cell Lung Cancer
Similar Researchers
Based on overlapping research topics
Lora J. Rogers
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Prostate Cancer Treatment and Research
Ebrahim Jakoet
University of Arkansas at Little Rock
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Lung Cancer Diagnosis and Treatment
Aya Almashad
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Prostate Cancer Treatment and Research
Medical Case Reports
Emily Kanwischer
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Lung Cancer Diagnosis and Treatment
SARS-CoV-2 and COVID-19 Research
Volodymyr Tryndyak
National Center for Toxicological Research
Cancer-related molecular mechanisms research
Epigenetics and DNA Methylation
Diet and metabolism studies
Konstantinos Arnaoutakis
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Lung Cancer Diagnosis and Treatment
Medical Case Reports